Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EHA 2024 | The current role of plasmapheresis in the treatment landscape for TTP

Eleni Gavriilaki • 13 Jun 2024
EHA 2024
Rare Diseases Antibodies Caplacizumab

Eleni Gavriilaki, MD, PhD, Aristotle University of Thessaloniki, Thessaloniki, Greece, discusses the current role of plasmapheresis in the treatment landscape of thrombotic thrombocytopenic purpura (TTP). While plasmapheresis has been the standard of care for this disease for the last decade, new drugs such as caplacizumab for immune or acquired TTP or recombinant ADAMTS13 for congenital TTP have shown great promise and are currently undergoing trials to determine whether they could replace plasma exchange therapy. This interview took place at the 29th Congress of the European Hematology Association (EHA) in Madrid, Spain.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Eleni Gavriilaki

The current approach to response assessment in TA-TMA
1:36
The current approach to response assessment in TA-TMA
Eleni Gavriilaki • 25 Mar 2026
The current approach to severity scoring in TA-TMA
1:21
The current approach to severity scoring in TA-TMA
Eleni Gavriilaki • 25 Mar 2026
Moving the field forward in TA-TMA: insights from an educational session
2:26
Moving the field forward in TA-TMA: insights from an educational session
Eleni Gavriilaki • 25 Mar 2026
Endothelial injury syndromes in hematology: unifying the terminology
1:44
Endothelial injury syndromes in hematology: unifying the terminology
Eleni Gavriilaki • 13 Jun 2025

Related Videos

LENAZART: lenalidomide, oral azacitidine, & radiotherapy in newly diagnosed & relapsed plasmacytoma
3:31
LENAZART: lenalidomide, oral azacitidine, & radiotherapy in newly diagnosed & relapsed plasmacytoma
Urvi Shah • 25 Sep 2026
BPDCN: unmet needs, CD123-targeted therapies and novel targets
15:50
BPDCN: unmet needs, CD123-targeted therapies and novel targets
Naveen Pemmaraju • 19 Sep 2026
Phase III CARES: survival and cardiovascular outcomes with anselamimab in cardiac AL amyloidosis
2:19
Phase III CARES: survival and cardiovascular outcomes with anselamimab in cardiac AL amyloidosis
Ashutosh Wechalekar • 9 Sep 2026
Managing solitary plasmacytomas: importance of accurate imaging and bone marrow assessment
1:39
Managing solitary plasmacytomas: importance of accurate imaging and bone marrow assessment
Elena Zamagni • 25 Sep 2026

Choose your cookie settings

VJHemOnc uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJHemOnc is intended for healthcare professionals